Jiangsu Hengrui Pharmaceuticals (600276.SH): RSS0393 ointment approved for clinical trials.
Hengrui Medicine (600276.SH) issued an announcement that recently, its subsidiary Ruishi Biopharmaceutical Co., Ltd. received a letter from the country...
Jiangsu Hengrui Pharmaceuticals (600276.SH) has announced that its subsidiary Ruishi Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials on the RSS0393 ointment. The ointment, developed by the company, contains a small molecule inhibitor of PDE4 which can relieve tissue damage and inflammation by inhibiting the activity of PDE4 in various cells. The clinical trials will commence soon.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
